USPTOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The US trademark BLYS was filed as Word mark on 09/03/1999 at the U.S. Patent and Trademark Office.
It was registered as a trademark on 08/10/2004.
The current status of the mark is "CANCELLED - SECTION 8".
| Trademark form | Word mark |
| File reference | 75792415 |
| Register number | 2871946 |
| Application date | September 3, 1999 |
| Publication date | January 30, 2001 |
| Entry date | August 10, 2004 |
Trademark owner
14200 Shady Grove Road
20850 Rockville
US
20850 Rockville
US
Trademark representatives
goods and services
5
proteins for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; nucleic acids for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; pharmaceutical preparations containing proteins for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; pharmaceutical preparations containing nucleic acids for the treatment of immune deficiency syndromes, cancer, AIDS, infectious diseases, allergies, asthma and autoimmunity; proteins for the enhancement of B cell activity and immunoglobulin production following organ transplant, bone marrow transplant, vaccine administration, immunosuppression, chemotherapy, radio therapy, antibiotic therapy, and gene therapy; nucleic acids for the enhancement of B cell activity and immunoglobulin production following organ transplant, bone marrow transplant, vaccine administration, immunosuppression, chemotherapy, radio therapy, antibiotic therapy, and gene therapy; pharmaceutical preparations containing proteins for the enhancement of B cell activity and immunoglobulin production following organ transplant, bone marrow transplant, vaccine administration, immunosuppression, chemotherapy, radio therapy, antibiotic therapy, and gene therapy; and pharmaceutical preparations containing nucleic acids for the enhancement of B cell activity and immunoglobulin production following organ transplant, bone marrow transplant, vaccine administration, immunosuppression, chemotherapy, radio therapy, antibiotic therapy, and gene therapy
ID: 1375792415